What the FDA labels say about taking them together
Pimavanserin and procainamide
Pimavanserin's FDA label of June 18, 2026 names procainamide in its warnings and precautions section; the procainamide label PlainMeds reads does not name pimavanserin. The pimavanserin label: “The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain …”
Check it at the source: the pimavanserin FDA label on DailyMed (effective June 18, 2026, Acadia Pharmaceuticals Inc.); the procainamide FDA label on DailyMed (effective February 17, 2025, Caplin Steriles Limited).
What does the pimavanserin label say about procainamide?
Pimavanserin label, warnings and precautionsThe use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin) [see Drug Interactions (7.1) ].
Source: FDA drug label (NUPLAZID), Acadia Pharmaceuticals Inc., effective June 18, 2026 (SPL set 1e6bea44-57d6-4bac-9328-46e1ee59f83b), via openFDA; the full label on DailyMed
What does the procainamide label say about pimavanserin?
Procainamide's label (effective February 17, 2025) does not name pimavanserin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Procainamide Hydrochloride), Caplin Steriles Limited, effective February 17, 2025 (SPL set fcaa5e9a-3c8a-4796-aa87-626268b6cf60), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Pimavanserin | Procainamide | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $170.50 per capsule 34 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once